News & Updates

Vitamin D supplementation exerts no effect on psoriasis severity in vitamin D-deficient individuals
Vitamin D supplementation exerts no effect on psoriasis severity in vitamin D-deficient individuals
22 May 2023
Individuals with vitiligo less prone to melanoma, skin cancer
Individuals with vitiligo less prone to melanoma, skin cancer
08 May 2023

The incidence of melanoma and nonmelanoma skin cancer appears to be markedly low among people with vitiligo, as reported in a study.

Individuals with vitiligo less prone to melanoma, skin cancer
08 May 2023
People with alopecia areata prone to anxiety, depression
People with alopecia areata prone to anxiety, depression
07 May 2023

Patients with alopecia areata (AA) are more susceptible to both anxiety and depression, according to the results of a systematic review and meta-analysis.

People with alopecia areata prone to anxiety, depression
07 May 2023
Second primary melanoma tied to better survival than single primary lesion
Second primary melanoma tied to better survival than single primary lesion
06 May 2023

Patients who present with second primary melanomas have better survival and thinner lesions than those presenting with single primary melanomas, reveals a study.

Second primary melanoma tied to better survival than single primary lesion
06 May 2023
Tralokinumab a promising treatment option in young people with moderate-to-severe AD
Tralokinumab a promising treatment option in young people with moderate-to-severe AD
29 Apr 2023
SG: Acne in youths managed suboptimally in primary care
SG: Acne in youths managed suboptimally in primary care
19 Apr 2023 byJairia Dela Cruz

The prescribing patterns for acne among local primary care physicians appear to deviate from clinical practice guidelines used to achieve optimal outcomes for young people, as shown in a Singapore study.

SG: Acne in youths managed suboptimally in primary care
19 Apr 2023
Apremilast safe, effective in moderate-to-severe genital psoriasis
Apremilast safe, effective in moderate-to-severe genital psoriasis
13 Apr 2023 byStephen Padilla

Treatment with apremilast demonstrates consistent efficacy in genital psoriasis and overall psoriasis symptoms at 16 weeks irrespective of body surface area (BSA) at baseline, suggest the results of the phase III DISCREET trial presented at the recent AAD 2023.

Apremilast safe, effective in moderate-to-severe genital psoriasis
13 Apr 2023